Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $16 | $16 | $36 | $23 |
| Short-Term Investments | $36 | $77 | $32 | $85 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $7 | $6 | $7 |
| Total Curr. Assets | $55 | $100 | $74 | $115 |
| Property Plant & Equip (Net) | $0 | $7 | $6 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $3 | $0 | $10 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $1 | $0 |
| Total NC Assets | $0 | $10 | $7 | $12 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $55 | $110 | $81 | $126 |
| Liabilities | – | – | – | – |
| Payables | $2 | $1 | $3 | $4 |
| Short-Term Debt | $0 | $1 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $6 | $2 | $2 |
| Other Curr. Liab. | $6 | $0 | $0 | $0 |
| Total Curr. Liab. | $8 | $8 | $8 | $8 |
| LT Debt | $0 | $0 | $1 | $3 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $2 | $0 | $1 | $3 |
| Other Liabilities | -$2 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $8 | $8 | $9 | $11 |
| Equity | – | – | – | – |
| Pref Stock | $55 | $110 | $81 | $126 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$212 | -$142 | -$91 | -$43 |
| AOCI | -$0 | -$0 | $0 | $0 |
| Other Equity | -$55 | $133 | -$81 | -$126 |
| Total Equity | -$212 | $101 | -$91 | -$43 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $55 | $110 | -$81 | -$32 |
| Net Debt | -$16 | -$15 | -$33 | -$18 |